Wedbush Reiterates “Outperform” Rating for Inozyme Pharma (NASDAQ:INZY)

Inozyme Pharma (NASDAQ:INZY – Get Free Report)‘s stock had its “outperform” rating restated by equities researchers at Wedbush in a note issued to investors on Tuesday, Benzinga reports. They presently have a $15.00 price objective on the stock. Wedbush’s price objective suggests a potential upside of 172.73% from the stock’s previous close. Separately, Needham & […]

Leave a Reply

Your email address will not be published.

Previous post Heartland Financial USA (NASDAQ:HTLF) Stock Rating Reaffirmed by Stephens
Next post Lakeland Industries (NASDAQ:LAKE) Stock Rating Lowered by StockNews.com